Denali Therapeutics Inc (DNLI) Shares Sold by Zurcher Kantonalbank Zurich Cantonalbank

Share on StockTwits

Zurcher Kantonalbank Zurich Cantonalbank reduced its stake in Denali Therapeutics Inc (NASDAQ:DNLI) by 6.6% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,748 shares of the company’s stock after selling 688 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Denali Therapeutics were worth $226,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Bank of New York Mellon Corp boosted its stake in Denali Therapeutics by 232.9% in the 3rd quarter. Bank of New York Mellon Corp now owns 203,696 shares of the company’s stock worth $4,428,000 after purchasing an additional 142,500 shares during the period. Jane Street Group LLC acquired a new stake in shares of Denali Therapeutics in the 3rd quarter valued at $218,000. Man Group plc acquired a new stake in shares of Denali Therapeutics in the 3rd quarter valued at $228,000. Teachers Advisors LLC lifted its stake in shares of Denali Therapeutics by 166.2% in the 3rd quarter. Teachers Advisors LLC now owns 92,671 shares of the company’s stock valued at $2,015,000 after purchasing an additional 57,863 shares during the last quarter. Finally, TIAA CREF Investment Management LLC lifted its stake in shares of Denali Therapeutics by 101.4% in the 3rd quarter. TIAA CREF Investment Management LLC now owns 72,701 shares of the company’s stock valued at $1,581,000 after purchasing an additional 36,599 shares during the last quarter. Institutional investors own 71.41% of the company’s stock.

Several equities research analysts recently issued reports on DNLI shares. ValuEngine lowered shares of Denali Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 29th. Cantor Fitzgerald lowered shares of Denali Therapeutics from an “overweight” rating to a “neutral” rating and set a $25.00 price objective for the company. in a research note on Tuesday, January 29th. Finally, Zacks Investment Research raised shares of Denali Therapeutics from a “hold” rating to a “buy” rating and set a $31.00 price objective for the company in a research note on Tuesday, April 9th.

In related news, COO Alexander O. Schuth sold 7,500 shares of Denali Therapeutics stock in a transaction on Monday, May 13th. The shares were sold at an average price of $22.05, for a total value of $165,375.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Ryan J. Watts sold 18,333 shares of Denali Therapeutics stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $22.18, for a total transaction of $406,625.94. The disclosure for this sale can be found here. Insiders sold a total of 96,000 shares of company stock worth $2,279,169 in the last quarter. Insiders own 21.20% of the company’s stock.

Shares of DNLI opened at $20.68 on Friday. The firm has a market capitalization of $2.06 billion, a P/E ratio of -53.03 and a beta of 2.03. Denali Therapeutics Inc has a one year low of $12.32 and a one year high of $28.86. The company has a current ratio of 11.55, a quick ratio of 11.55 and a debt-to-equity ratio of 0.14.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Wednesday, May 8th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.01). The firm had revenue of $4.21 million during the quarter, compared to the consensus estimate of $12.88 million. Denali Therapeutics had a negative return on equity of 10.23% and a negative net margin of 38.84%. On average, research analysts expect that Denali Therapeutics Inc will post -1.42 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was first posted by Week Herald and is the property of of Week Herald. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://weekherald.com/2019/05/17/denali-therapeutics-inc-dnli-shares-sold-by-zurcher-kantonalbank-zurich-cantonalbank.html.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.

See Also: How does equity income fit into an investing strategy?

Want to see what other hedge funds are holding DNLI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Denali Therapeutics Inc (NASDAQ:DNLI).

Institutional Ownership by Quarter for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.